Hemagglutination and graft-versus-host disease in the severe combined immunodeficiency mouse lymphoproliferative disease model

SJ Pirruccello, H Nakamine, KW Beisel, KL Kleveland, M Okano, Y Taguchi, JR Davis, ML Mahloch and DT Purtilo
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198-6495.

In the course of evaluating the severe combined immunodeficiency mouse- human peripheral blood lymphocyte (SCID-PBL) model of lymphoproliferative disease, we noted hemagglutination occurring in peripheral blood smears of mice with serum human immunoglobulin levels greater than 1.0 mg/ml. The hemagglutinating process was mediated by human anti-mouse red cell antibodies of the IgM class, peaked at five to seven weeks post-transfer of 5 to 7 x 10(7) human PBL and was generally self limiting. However, death resulted in some mice when serum immunoglobulin levels were greater than 3.0 mg/ml. The most severely affected mice had hemagglutination induced congestion of liver, lungs and spleen. Several mice also had lesions consistent with graft-versus-host disease (GVHD) including focal hepatic necrosis and destruction of mouse splenic hematopoietic elements. The lesions associated with hemagglutination and GVHD in SCID-PBL mice are distinct from those associated with EBV-induced lymphoproliferation. Recognition of these pathologic processes are required for a thorough understanding of the SCID-PBL model.

This article has been cited by other articles:

S. Garcia, G. Dadaglio, and M.-L. Gougeon
Limits of the Human-PBL-SCID Mice Model: Severe Restriction of the Vbeta T-Cell Repertoire of Engrafted Human T Cells
Blood, January 1, 1997; 89(1): 329 - 336.
[Abstract] [Full Text] [PDF]

REGULAR ARTICLES

Hemagglutination and graft-versus-host disease in the severe combined immunodeficiency mouse lymphoproliferative disease model